Cargando…

The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells

BACKGROUND: Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p...

Descripción completa

Detalles Bibliográficos
Autores principales: Garufi, Alessia, Ubertini, Valentina, Mancini, Francesca, D’Orazi, Valerio, Baldari, Silvia, Moretti, Fabiola, Bossi, Gianluca, D’Orazi, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546314/
https://www.ncbi.nlm.nih.gov/pubmed/26297485
http://dx.doi.org/10.1186/s13046-015-0206-x
_version_ 1782386901547745280
author Garufi, Alessia
Ubertini, Valentina
Mancini, Francesca
D’Orazi, Valerio
Baldari, Silvia
Moretti, Fabiola
Bossi, Gianluca
D’Orazi, Gabriella
author_facet Garufi, Alessia
Ubertini, Valentina
Mancini, Francesca
D’Orazi, Valerio
Baldari, Silvia
Moretti, Fabiola
Bossi, Gianluca
D’Orazi, Gabriella
author_sort Garufi, Alessia
collection PubMed
description BACKGROUND: Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p53/DNA binding to induce canonical target genes. Mutant p53 proteins undergo protein misfolding that can be counteracted by zinc. However, whether zinc supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with drugs, has not been addressed so far. METHODS: In this study we compared the effect of two antitumor treatments: on the one hand wild-type p53-carrying colon cancer cells were treated with low and high doses of chemotherapeutic agent Adriamycin and, on the other hand, Adriamycin was used in combination with ZnCl(2). Biochemical and molecular analyses were applied to evaluate p53 activity and biological outcomes in this setting. Finally, the effect of the different combination treatments were applied to assess tumor growth in vivo in tumor xenografts. RESULTS: We found that low-dose Adriamycin did not induce p53 activation in wtp53-carrying colon cancer cells, unless in combination with ZnCl(2). Mechanistically, ZnCl(2) was a key determinant in inducing wtp53/DNA binding and transactivation of target genes in response to low-dose Adriamycin that used alone did not achieve such effects. Finally, in vivo studies, in a model of wtp53 colon cancer xenograft, show that low-dose Adriamycin did not induce tumor regression unless in combination with ZnCl(2) that activated endogenous wtp53. CONCLUSIONS: These results provide evidence that ZnCl(2) might be a valuable adjuvant in chemotherapeutic regimens of colorectal cancer harboring wild-type p53, able to both activate p53 and reduce the amount of drugs for antitumor purposes.
format Online
Article
Text
id pubmed-4546314
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45463142015-08-23 The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells Garufi, Alessia Ubertini, Valentina Mancini, Francesca D’Orazi, Valerio Baldari, Silvia Moretti, Fabiola Bossi, Gianluca D’Orazi, Gabriella J Exp Clin Cancer Res Research BACKGROUND: Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p53/DNA binding to induce canonical target genes. Mutant p53 proteins undergo protein misfolding that can be counteracted by zinc. However, whether zinc supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with drugs, has not been addressed so far. METHODS: In this study we compared the effect of two antitumor treatments: on the one hand wild-type p53-carrying colon cancer cells were treated with low and high doses of chemotherapeutic agent Adriamycin and, on the other hand, Adriamycin was used in combination with ZnCl(2). Biochemical and molecular analyses were applied to evaluate p53 activity and biological outcomes in this setting. Finally, the effect of the different combination treatments were applied to assess tumor growth in vivo in tumor xenografts. RESULTS: We found that low-dose Adriamycin did not induce p53 activation in wtp53-carrying colon cancer cells, unless in combination with ZnCl(2). Mechanistically, ZnCl(2) was a key determinant in inducing wtp53/DNA binding and transactivation of target genes in response to low-dose Adriamycin that used alone did not achieve such effects. Finally, in vivo studies, in a model of wtp53 colon cancer xenograft, show that low-dose Adriamycin did not induce tumor regression unless in combination with ZnCl(2) that activated endogenous wtp53. CONCLUSIONS: These results provide evidence that ZnCl(2) might be a valuable adjuvant in chemotherapeutic regimens of colorectal cancer harboring wild-type p53, able to both activate p53 and reduce the amount of drugs for antitumor purposes. BioMed Central 2015-08-22 /pmc/articles/PMC4546314/ /pubmed/26297485 http://dx.doi.org/10.1186/s13046-015-0206-x Text en © Garufi et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Garufi, Alessia
Ubertini, Valentina
Mancini, Francesca
D’Orazi, Valerio
Baldari, Silvia
Moretti, Fabiola
Bossi, Gianluca
D’Orazi, Gabriella
The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
title The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
title_full The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
title_fullStr The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
title_full_unstemmed The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
title_short The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
title_sort beneficial effect of zinc(ii) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546314/
https://www.ncbi.nlm.nih.gov/pubmed/26297485
http://dx.doi.org/10.1186/s13046-015-0206-x
work_keys_str_mv AT garufialessia thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT ubertinivalentina thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT mancinifrancesca thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT dorazivalerio thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT baldarisilvia thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT morettifabiola thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT bossigianluca thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT dorazigabriella thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT garufialessia beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT ubertinivalentina beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT mancinifrancesca beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT dorazivalerio beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT baldarisilvia beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT morettifabiola beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT bossigianluca beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells
AT dorazigabriella beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells